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Abstract: Type-2 diabetes (T2D) is one of the fastest growing chronic diseases worldwide. The PREVIEW
project has been initiated to find the most effective lifestyle (diet and physical activity) for
the prevention of T2D, in overweight and obese participants with increased risk for T2D. The
study is a three-year multi-centre, 2 × 2 factorial, randomised controlled trial. The impact of a
high-protein, low-glycaemic index (GI) vs. moderate protein, moderate-GI diet in combination
with moderate or high-intensity physical activity on the incidence of T2D and the related clinical
end-points are investigated. The intervention started with a two-month weight reduction using a
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low-calorie diet, followed by a randomised 34-month weight maintenance phase comprising four
treatment arms. Eight intervention centres are participating (Denmark, Finland, United Kingdom,
The Netherlands, Spain, Bulgaria, Australia, and New Zealand). Data from blood specimens, urine,
faeces, questionnaires, diaries, body composition assessments, and accelerometers are collected at
months 0, 2, 6, 12, 18, 24, and 36. In total, 2326 adults were recruited. The mean age was 51.6 (SD 11.6)
years, 67% were women. PREVIEW is, to date, the largest multinational trial to address the prevention
of T2D in pre-diabetic adults through diet and exercise intervention. Participants will complete the
final intervention in March, 2018.
Keywords: diet; protein; carbohydrate; glycaemic index; physical activity; obesity
1. Introduction
Type-2 diabetes (T2D) is a disease associated with serious comorbidities, including microvascular
(retinopathy, nephropathy, neuropathy) and macrovascular (cardiovascular) events [1]. The estimated
global prevalence is approximately 8% and a prediction suggests that this will increase by 55% up to
the year 2035 [2,3]. An important risk factor for T2D is obesity (BMI > 30 kg/m2) predicting a more
than 10-fold increase in incidence compared to normal weight [4]. Weight gain during adulthood is
also an independent risk factor for T2D [5], as are genetic inheritance, unhealthy dietary habits, and
insufficient physical activity [6–8].
Long-term studies have shown benefits of a lifestyle intervention (diet and exercise), on T2D
incidence in China [9], USA [10], and Finland [11]. Lifestyle change (diet, physical activity, weight
loss) may reduce the incidence of T2D by 28–59% [12]. The American Diabetes Prevention Program
(DPP) [13], the Finnish Diabetes Prevention Study (DPS) [14], and the Chinese Da Qing Diabetes
Prevention Study [15] were all designed to produce weight loss by prescribing a higher carbohydrate
(CHO) (>50 percent of energy (E%) from CHO), low-fat (<30 E%) diet approach, which reflected the
understanding of a prudent diet 20 years ago. No attention was paid to glycaemic index (GI), per se,
and, to date, no studies have investigated the role of GI for prevention of type-2 diabetes.
Other dietary prescriptions that produce significant and sustainable weight loss may also be
effective in T2D prevention. Current international recommendations include lower ranges for CHO
intake [16] and a recommendation to choose lower GI foods [17]. A combination of lower CHO (45 E%),
higher protein, together with lower GI, might be the optimal diet for prevention of T2D [18], perhaps
related to sustained weight loss as shown in medium term trials [19]. To date these hypotheses have
not been tested in large trials of long duration [20].
The program for physical activity in the trials described above followed the international public
health recommendations, that is, a total of approximately 150 min per week of moderate-intensity
aerobic activities or 75 min of vigorous intensity activity [10,14]. A question, not examined in
earlier studies, is whether the metabolic responses are different between higher- and lower-intensity
exercise programs. Moderate-intensity exercise relies relatively more on fat oxidation, whereas
vigorous-intensity exercise relies more on CHO oxidation and use of intramuscular substrates [21].
Houmard et al. found that total exercise time, not intensity or exercise energy expenditure, was associated
with the greatest improvement of insulin sensitivity in obese participants [22]. However, the hypothesis
that physical activity with different intensity levels may differentially affect T2D prevention has yet to
be tested in any large-scale intervention.
Since obesity is a strong risk factor for T2D, any successful prevention program should be able
to prevent weight regain in individuals after a significant weight loss. The high heterogeneity of
dietary intervention design prevents firm conclusions being drawn regarding preferred macronutrient
composition [23]. Notably a recent multi-centre trial ‘DiOGenes’ (Diet, Obesity, and Genes) identified a
higher-protein, moderate-CHO, and low-GI diet as superior to other diets of varying macronutrient
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composition in preventing weight regain over six months [19] and in a smaller subset over
12 months [24], after two months of rapid weight loss.
Despite the evidence that a lifestyle program combining prudent diet, increased physical activity
and weight loss reduces the risk for T2D in susceptible individuals [12], important details remain
unanswered. These include the long-term effects and sustainability of diets higher in protein with
a lower glycaemic load, combined with the effects of higher intensity exercise. The present paper
describes PREVention of diabetes through lifestyle Intervention and population studies in Europe and
around the World (PREVIEW), a large multi-centre international randomised controlled trial in adults
designed to answer these questions.
2. Methods
2.1. Aims of the Study
The aim is to determine the effects and interactions of two diets and two physical activity
programmes on the prevention of T2D in overweight, pre-diabetic adults, who have undergone a short
period of significant weight loss. Our primary hypothesis is that a higher protein, lower CHO/low GI
diet (based on the DiOGenes study [19]) will be superior in preventing T2D when compared with a
moderate protein, higher CHO/moderate GI diet (based on the DPS and DPP studies [10,14]). We also
hypothesise that high-intensity physical activity will be superior compared to moderate-intensity
physical activity [25].
Each participant receives one of the two dietary programs, and one of the two physical activity
programs, thus, we have four groups (high protein diet and high-intensity physical activity; moderate
protein diet and high-intensity physical activity; high protein diet and moderate-intensity physical
activity; moderate-protein diet and moderate-intensity physical activity). The majority of outcomes
will be analysed by using these four arms. The primary endpoint and statistical power calculations are
based on a two-arm design (diets compared against each other).
2.2. Primary and Secondary Endpoints
The primary endpoint is incidence of T2D in high vs. moderate protein diet measured over a
36-month intervention period, based on the WHO criteria [26] of either (i) oral glucose tolerance test
(OGTT) with fasting plasma glucose (FPG) > 7.0 mmol/L and/or 2-h post prandial (75 g glucose
load) plasma glucose ≥11.1 mmol/L; or (ii) T2D diagnosed by a medical doctor between the clinical
investigation days (CID) of PREVIEW, by using random plasma glucose≥11.1 mmol/L in the presence
of symptoms of diabetes, OGTT, or glycated haemoglobin (HbA1c). Asymptomatic individuals with
a single abnormal value will have to repeat the test within 2–4 weeks to confirm the T2D diagnosis.
The secondary endpoints include changes in HbA1c, body weight, body mass index (BMI), waist, and
thigh circumference, body composition, insulin sensitivity, including Matsuda Index [27], glucose
tolerance assessed by the area under the curve during OGTT, blood pressure, serum lipids, C-reactive
protein, liver enzymes, perceived quality of life and work ability, habitual well-being, sleep, chronic
stress, and subjective appetite sensations.
Other endpoints assessed by sub-group studies include liver fat content using magnetic resonance
imaging (MRI) and proton magnetic resonance spectroscopy (H-MRS); colorectal cancer risk assessed
from faecal markers; gut microbiome community assessment from faecal collections; maximal
oxygen uptake capacity (VO2 max); urine metabolite profiles using metabolomic techniques and
food reward outcomes.
2.3. Study Setting and Design
The PREVIEW intervention study for adult participants has eight study sites: University of
Copenhagen (Denmark), University of Helsinki (Finland), University of Maastricht (The Netherlands),
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University of Nottingham (UK), University of Navarra (Spain), Medical University of Sofia (Bulgaria),
University of Sydney (Australia), and University of Auckland (New Zealand).
The 36-month intervention consists of two phases (Figure 1): a two-month period of rapid weight
reduction achieved using a commercial low-calorie diet (about 800 kcal/day), followed by a 34-month
randomised lifestyle (diet and physical activity) intervention phase for weight loss maintenance.Nutrients 2017, 9, 632 4 of 17 
 
 
Figure 1. PREVIEW intervention: the general study design. 
Clinical investigation days (CID) are conducted throughout the intervention, from CID1 
(baseline) to CID7 (end of trial). At CID visits, anthropometry, blood tests, and questionnaires are 
performed and collection of completed diet records, accelerometers, and 24-h urine samples is done. 
Adverse (AE) and serious adverse events (SAE) and concomitant medications are recorded. In 
addition, a total of 17 group visits, leaded by instructors, are held throughout the trial to support 
lifestyle modification. 
The CID assessments and group visits are conducted within University settings or associated 
Clinics. Participants follow the diet and physical activity counselling advice in a “real-life” setting 
without daily supervision from researchers. 
2.4. Participants, Recruitment, and Randomisation 
The inclusion criteria were: age 25–70 years (from mid-2013 to mid-2014 individuals aged 25–45 
and 55–70 years were enrolled, and from mid-2014 onwards additionally age-group 45–54 years); 
BMI > 25 kg/m2; pre-diabetes confirmed by an OGTT using the American Diabetes Association (ADA) 
criteria (13): (i) increased fasting glucose (IFG), with venous plasma glucose concentration of 5.6–6.9 
mmol/L when fasted; and/or (ii) impaired glucose tolerance (IGT), with venous plasma glucose 
concentration of 7.8–11.0 mmol/L at 2 h after oral administration of standard 75 g glucose dose, and 
fasting plasma glucose <7.0 mmol/L. The main exclusion criteria were T2D, and any illness and/or 
medication with known or potential effect on compliance (e.g., unable to follow the physical activity 
program) or the main outcomes. A complete list of inclusion and exclusion criteria is presented as 
Supplementary Table S1. 
Participants were recruited using multiple methods across the eight study sites, e.g., newspaper 
advertisements, newsletters, radio and television advertisements/interviews, and direct contact with 
primary and occupational health care providers. Interested individuals were contacted for the pre-
screening. In the interview, inclusion and exclusion criteria were queried, including the Finnish 
Diabetes Risk Score [28] assessment. Potential participants were given written and oral information. 
Signed informed consent was required prior to commencement of laboratory screening. 
The laboratory screening comprised measurements of weight, height, resting blood pressure, 
electrocardiography (in those aged 55 years or more), and an OGTT. A fasting blood sample was 
collected from the ante-cubital vein for later assessment of full inclusion and exclusion criteria, whilst 
glucose concentration was immediately analysed at each study site (HemoCue™, Angelholm, 
Sweden; Reflotron™, Roche diagnostics, Switzerland; or EML105 Radiometer, Copenhagen). 
Participants were then given a standard glucose drink (75 g glucose, dissolved in 300 mL water), 
which they had to take within 3–5 min, and a second venous blood sample was collected after 2 h. 
No other food or drinks or smoking were allowed and participants were required to remain sedentary 
during the test. The 0 and 2 h glucose concentration were used to identify those with pre-diabetes. 
Potentially eligible participants had fasting blood samples analysed to assess safety with 
haemoglobin, creatinine and alanine (ALT)/aspartate transaminase (AST). 
Figure 1. PREVIEW intervention: the general study design.
Cli ical investigation days (CID) are conducted throughout the interventio , from CID1 (baseline)
to CID7 (end of trial). At CID visits, anthropomet y, blood tests, and questionnai es are performed and
collection of completed diet records, accelerometers, and 24-h urine samples is don . Adverse (AE)
an serious adverse events (SAE) and concomitant medications are recorded. In add tion, a total of
17 group visits, le ded by instructors, are held throughout the trial to support lifestyle modification.
The CID as es ments and group visits are c i ersity se tings or a sociated
Clinics. Participants follo the diet a i l i i selling advice in a “real-life” setting
without daily supervision from researchers.
2.4 Participants, Recruitment, and Rando isatio
The inclusion criteria were: age 25– t id-2014 individuals aged 25–45
and 55–70 years were enrolled, and fro i itionally age-group 45–54 years);
BMI > 2 m2; pre-diab tes confirmed by an OGTT using the American Diabetes Association
(ADA) criteria (13): (i) increased fasting glucose (IFG), with venous plasma glucose concentration
of 5.6–6.9 mmol/L when fasted; and/or (ii) impaired glucose tolerance (IGT), with venous plasma
glucose concentration of 7.8–11.0 mmol/L at 2 h after oral administration of standard 75 g glucose
dose, and fasting plasma glucose <7.0 mmol/L. The main exclusion criteria were T2D, and any illness
and/or medication with known or potential effect on compliance (e.g., unable to follow the physical
activity program) or the main outcomes. A complete list of inclusion and exclusion criteria is presented
as Supplementary Table S1.
Participants were recruited using multiple methods across the eight study sites, e.g., newspaper
advertisements, newsletters, radio and television advertisements/interviews, and direct contact
with primary and occupational health care providers. Interested individuals were contacted for the
pre-screening. In the interview, inclusion and exclusion criteria were queried, including the Finnish
Diabetes Risk Score [28] assessment. Potential participants were given written and oral information.
Signed informed consent was required prior to commencement of laboratory screening.
The laboratory screening comprised measurements of weight, height, resting blood pressure,
electrocardiography (in those aged 55 years or more), and an OGTT. A fasting blood sample was
collected from the ante-cubital vein for later assessment of full inclusion and exclusion criteria, whilst
glucose concentration was immediately analysed at each study site (HemoCue™, Angelholm, Sweden;
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Reflotron™, Roche diagnostics, Switzerland; or EML105 Radiometer, Copenhagen). Participants were
then given a standard glucose drink (75 g glucose, dissolved in 300 mL water), which they had to
take within 3–5 min, and a second venous blood sample was collected after 2 h. No other food or
drinks or smoking were allowed and participants were required to remain sedentary during the test.
The 0 and 2 h glucose concentration were used to identify those with pre-diabetes. Potentially eligible
participants had fasting blood samples analysed to assess safety with haemoglobin, creatinine and
alanine (ALT)/aspartate transaminase (AST).
Upon confirmation of eligibility, participants were enrolled into the trial and randomised to one
of the four treatment groups. Randomisation was stratified by gender and age group (25–45, 46–54,
and 55–70 years of age), and sequentially assigned from each stratum to different interventions, hence,
securing an even distribution of gender and age group over the four intervention arms in each centre.
2.5. Description of Interventions
2.5.1. Low-Calorie Diet (LCD)
The trial started with a two-month (eight-week) weight reduction program using a commercial
LCD, with a requirement to lose >8% initial body weight in order to continue to the weight maintenance
phase. The LCD consisted of 3.4 MJ (800 kcal), 15–20 E% fat, 35–40 E% protein (84 g protein),
and 45–50 E% CHO. The daily diet comprised of 4 × 40 g Cambridge Weight Plan® meal replacement
sachets (Cambridge Weight Plan Ltd., Corby, UK), three of which were dissolved in 250 mL low fat
milk ,or similar lactose-free alternatives, and one in 250 mL water. Energy-free drinks were permitted.
Moreover, a maximum of 400 g of non-starchy, low-CHO vegetables, such as lettuce, asparagus,
broccoli, celery, cucumber, mushrooms, radish, tomato, and watercress could be consumed.
During the LCD, participants attended group visits at weeks 2, 4, 6, and 8. Body weight,
AE, SAE, and concomitant medications were recorded, LCD sachets dispensed, and dietary and
behavioural instructions given. No specific instructions on physical activity were given during the
LCD weight-reduction phase. Upon completion of the two months (CID2), participants who failed to
reach the target weight reduction (i.e., >8% of initial body weight) were excluded from the intervention.
2.5.2. Weight Maintenance Phase: Intervention Diets
The two intervention diets are described in Table 1. The moderate protein (MP) diet is based
on the DPS-dietary advice [14] aiming to reach a moderate protein (15 E%) and higher CHO (55 E%)
macronutrient distribution with at least moderate dietary GI (>56), following current recommendations
for prevention of T2D [17]. The (HP) diet has a higher protein (25 E%) and moderate CHO (45 E%)
distribution with lower dietary GI (<50), based on the most successful weight-loss maintenance diet in
the DiOGenes study [19]. Protein intake is higher and CHO intake is lower than the recommended
range for prevention of T2D [16,17].
Both intervention diets are moderate in fat (30 E%) and the target macronutrient profile and food
choices are supported by evidence for prevention of weight gain and/or T2D [8,23]. Notably, increased
intake of sugar-rich foods or refined grains is not encouraged as a means to reach the higher CHO
level, nor is increased consumption of red meat encouraged within the higher protein diet.
The diets are consumed ad libitum with respect to energy, with no provision of an individual
target for daily energy intake. Self-monitoring of total energy consumption is not required. However,
participants are instructed about controlling portion sizes of specific food types in order to achieve
the macronutrient and GI prescriptions, and in self-monitoring and adjustment of portion sizes in
general, in order to maintain their body weight loss. They are also encouraged to follow a regular meal
pattern. Additional weight reduction is allowed, but without anything other than adherence to the
maintenance diet and physical activity regimens.
The participants are given examples of daily eating plans with foods in appropriate proportions
to reflect the macronutrient and GI requirements of the two interventions. A food-exchange list assists
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in self-selected variety, whilst preserving the required macronutrient and GI levels. Cooking books
(one for each diet) with recipes suitable for all countries were specifically prepared for PREVIEW.
Table 1. Description of the PREVIEW dietary interventions.
Higher Protein (25 E% a)
Moderate Carbohydrate (45 E%)
Low GI b (≤50) Diet
Moderate Protein (15 E%)
Higher Carbohydrate (55 E%)
Medium GI (≥56) Diet
Comparison between the groups
• Protein intake higher
• Carbohydrate intake lower
• GI lower
• Protein intake lower
• Carbohydrate intake higher
• GI medium
Food items with increased use
(relative to the other group)
• Whole-grain cereals with low GI
• Pasta
• Low-fat dairy products
• Poultry
• Fish
• Legumes
• Whole-grain cereals with
moderate/high GI, e.g., bread
• Potatoes, sweet potatoes,
couscous, rice
• Bananas
Similar use
• Most fruits and vegetables
• Vegetable oils, margarine
• Red meat (decreased in both)
• Sugar-sweetened beverages (decreased in both)
a E%, percentage of energy; b GI, glycaemic index.
2.5.3. Weight Maintenance Phase: Physical Activity Programmes
The trial has two physical activity interventions with a similar target for energy expenditure
(>4.2 MJ/week, >1000 kcal/week), comprising high-intensity (HI) exercise or moderate-intensity (MI)
exercise, as shown in Table 2. Measured heart rate using a heart rate monitor or wrist palpation,
and/or perceived exertion using the Borg scale [29], are the principal methods of controlling the
intensity. The participants may choose from several exercise options with similar level of metabolic
turnover (energy expenditure divided by resting metabolic rate, i.e., MET values). The specific advice
is based on the U.S. Centres for Disease Control and Prevention (CDC) recommendations of 75 min
high-intensity (HI) or 150 min moderate-intensity (MI) physical activity weekly [30]. We developed a
leaflet and other written instruction materials for the two PA groups. Physical activity is generally not
supervised by the PREVIEW team, but participants are allowed to join supervised exercise groups of
their own choice.
Table 2. Description of the physical activity interventions.
High-Intensity Physical Activity (HI) Moderate-Intensity Physical Activity (MI)
Heart rate • 76–90% HRmax a or 61–80% HRR b • 60–75% HRmax or 45–60% HRR
Examples of activities
(these may vary depending on the
fitness level of the participant)
• Bicycling, vigorous effort
• Strenuous ball games
• Aerobics with very vigorous effort,
e.g., with extra weights
• Jogging > 8 km/h
• Swimming, vigorous effort
• Cross-country skiing
• Bicycling, moderate effort
• Leisurely ball games
• Most conditioning exercises
(aerobic, power yoga, etc.)
• Brisk walking (4–6 km/h)
• Swimming, recreational
• Downhill skiing
Weekly duration (in total) • at least 75 min • at least 150 min
Recommended weekly frequency • 2–3 times • 3–5 times
Daily duration (guideline) • 25–40 min • 30–50 min (may be broken down intoshorter sessions)
Additional exercises
• Muscle conditioning exercises, by using own weight: twice weekly at home,
15–20 min per session.
• Stretching: twice weekly, 15–20 min per session
a HRmax = max heart rate, defined as 220—age (220 in children under 16 years of age); b HRR = heart rate reserve,
defined as the difference between measured resting HR and estimated HRmax.
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A critical issue in PREVIEW is that many participants may be morbidly obese (BMI > 40)
and, therefore, their ability to cope with a high-intensity exercise program is likely to be limited,
and even risky. We addressed this point during the recruitments by specifically asking about perceived
competence in coping with our program, and by ECG in all volunteers aged >55 years. Moreover,
significant weight reduction (>8% of baseline body weight) during the first two months’ LCD period
will also simultaneously decrease the cardiovascular risks. The flexibility of our exercise program
(only target energy expenditure is specified, the modes of exercise are due to the participant) is also
likely to improve safety and adherence.
2.5.4. Group Visits and the Behavioural Modification Program
Group visits (8–12 individuals), are conducted throughout the three year intervention to deliver
the behaviour modification information in relation to diet and physical activity [31]. There are 17 group
visits, each 1–2 h, with decreasing frequency as the trial progresses. The behaviour modification
programme is developed based on theories and evidence from health psychology and behaviour
change [32–34]. For example, participants’ beliefs about the consequences of behaviour (i.e., outcome
expectancies), their intention to change their behaviour in the long run, and their belief in their ability
to achieve the behaviour change goals (self-efficacy) are relevant predictors of successful behaviour
change. Counsellors may apply respective behaviour change techniques [35] that are scheduled to
common stages of behaviour change [36].
At the beginning of the weight-maintenance phase (i.e., month 2), the participants are instructed
on how to plan, to start, and to follow the physical activity programme. In the group sessions,
the participants are also instructed on basic principles of increasing physical activity and in
motivational and self-regulative behaviour techniques to overcome barriers to exercise and behaviour
modification. Stretching and home-based muscle-conditioning exercises are also supervised in a
group-based session accompanied with written educational material [31].
2.6. Collection of Data and Description of Analyses
Data are collected from biological specimens (blood, urine, faecal), self-administered records
and questionnaires, and an activity-monitoring device (ActiGraph GT3X accelerometer; ActiGraph,
Pensacola, FL, USA) (see Table 3 with a description of timing). The CIDs are scheduled for a specific
week and the aim is to make the measurements as precisely as scheduled. To accommodate as complete
a data collection as possible we allow the following visit windows: month 2: −3 to +5 days; month 6:
±1 weeks; month 12: ±2 weeks; the remaining measurement points: ±4 weeks.
Blood samples are initially stored locally at −80 ◦C, then transported and analysed centrally at
the National Institution for Health and Welfare (THL) in Helsinki, Finland. Diet records are analysed
at each site using local food composition data and software. If available, local GI data for individual
food items are used, and when not available, generic global GI data are used. Accelerometer data are
downloaded at local sites, and collated and analysed centrally at the Swansea University, Wales, UK.
All questionnaires used in PREVIEW were prepared in English, then translated into the local
language in Finland, Denmark, The Netherlands, Spain, and Bulgaria using authorized translators.
A second authorized translator then back-translated the local versions to English, with this iterative
process repeated until a final version of sufficient quality was obtained.
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Table 3. Overview of data collection methods at different clinical investigation days (CID) in PREVIEW.
Outcome Data Collection Method Assessment Time-Points (Month)
0 2 6 12 18 24 36
CID1 CID2 CID3 CID4 CID5 CID6 CID7
Glucose tolerance/diagnosis
of T2D
75 g oral glucose
tolerance test × × × × ×
Blood chemistry
(lipid metabolism, glucose
metabolism, inflammation
markers, etc.)
Fasting venous
blood specimen × × × × × × ×
Urinary nitrogen 24-h urine collection × × × × ×
Risk markers for colon cancer
(e.g., Short Chain Fatty Acids) 3-day faecal collection
a × ×
Gut microbiota Faecal spot sample a × ×
Weight, height, BMI and
anthropometrics
Weight; height (week 0 and
156); waist and hip
circumference
× × × × × × ×
Body composition
Body composition by DXA,
BodPod or Bioelectrical
impedance (BIA)
× × × × × ×
Blood pressure and resting
heart rate
Resting blood pressure and
heart rate × × × × × × ×
Nutrient intakes, dietary GI
and food consumption 4-day food record × × × × ×
Physical activity
7-day accelerometer,
7-day physical activity log,
Baecke questionnaire
× × × × ×
Maximal oxygen uptake VO2 max test by ergometeror treadmill b × × ×
Psycho-social mediators and
moderators health behaviour
Several questionnaires
(listed with references in
Supplementary Table S2)
× × × × × ×
Eating behaviour Three Factor EatingQuestionnaire (TFEQ) × × × × × ×
Sleeping
Epworth Sleepiness Scale
(ESS), Pittsburgh Sleep
Quality Index (PSQI)
× × × × × ×
Stress and mood
Perceived Stress Scale (PSS),
Profile of Mood
Scale (POMS)
× × × × × ×
Quality of life WHO Quality of Lifequestionnaire x x x x
Work ability Work Ability Indexquestionnaire x x x x
Cost-effectiveness
Questionnaire designed
by the PREVIEW
research group
x x x x
a In a subgroup (n = 250) in Helsinki and Auckland; b In a subgroup (n = 120) in Copenhagen, Maastricht, Navarra
and Nottingham.
2.7. Data Management
All data are stored in a central project database at the University of Copenhagen. The central
database ensures standardized handling and storing of data and the possibility for easy extraction and
delivery of data both within and after the official project period (2013–2018).
Currently, the database receives input from four data sources on a regular basis: (1) All immediate
data measured (e.g., anthropometrics, blood glucose) and interviewed (e.g., use of medication) during
the CIDs and entered into OpenClinica server (electronic case report form); (2) data on social-cognitive
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determinants of behaviour, on cultural and socio-demographics, as well as socio-economic components,
are collected by the questionnaire delivery platform (QDP), designed for PREVIEW by NetUnion.
The participants enter their own data into the QDP. A paper version of the questionnaires is also
available; (3) physical activity is reported using the Baecke inventory, and an electronic physical activity
log (PAL), designed by Swansea University, University of Stuttgart, and implemented by NetUnion;
(4) the Central Lab at the National Institute for Health and Welfare (THL) enters all laboratory analyses
into the data hub. Data from analyses of the ActiGraph data accelerometers, from food diaries,
and from the maximal oxygen uptake (VO2 max) analyses are imported from all sites.
2.8. Governance and Quality Management
The intervention trial is led by Prof. Fogelholm at the University of Helsinki, in collaboration
with the project coordinator, Prof. Raben at the University of Copenhagen. In this large, international
multi-centre trial, we are collaborating intensively to ensure data collection of high-quality and
consistency of the intervention across all sites.
Specific working groups were formed with relevant site representatives. The purpose of these
working groups is to discuss and agree on questions related to dietary topics, physical activity, data
management, and other methodological and medical issues.
During the recruitment phase, principal investigators from each centre participated in a monthly
teleconference, which continues at regular intervals throughout the intervention.
The core personnel for each site meet annually at a three-day general assembly for the full
PREVIEW consortium. PREVIEW has a website [37] with both public access and a restricted area for
the PREVIEW researchers.
An electronic trial master file with relevant documents has been designed and is maintained by
the University of Copenhagen within the private part of the PREVIEW website. All written study
material is uploaded and made available at the PREVIEW website private area, including the protocol
and amendments, standard operating procedures (SOPs), and instruction materials for the intervention
subjects, in order ensure that comparable methods are followed across individual sites. The SOPs are
reviewed and revised as needed and also new SOPs are prepared, if necessary.
Representatives from each intervention site participated in two training sessions, each of 2–3 days
duration, in 2013. One session focussed on the main study protocol, the CID protocols, and all
outcome measurements (University of Copenhagen). The other session focused on instructor training
in group counselling (behaviour change) methods (University of Stuttgart). Attendees then trained
their local staff.
2.9. Statistical Power and Basic Analyses
The anticipated three-year incidence of T2D in the PREVIEW trial is 21%, based on data from
the Finnish DPS and US DPP [10,11]. The power calculation was derived for comparison of the two
dietary interventions (HP vs. MP).
It was hypothesized that a risk reduction of one quarter (1/4) in the MP group would reduce
the incidence of T2D incidence from 21% to 16%, and that a risk reduction of one half (1/2) in the
HP group would reduce the incidence of T2D from 21% to 10.5%. Consequently, the sample size
required to detect this difference in T2D incidence (16% vs. 10.5%) was at least 649 per diet group or
1298 participants in total (for a two-sided comparison with a power (1-ß) of 80% and p < 0.05), with
a 10% drop-out during the first 10 months from month 2 (CID2) onwards, and another 20% drop-out
between months 12 (CID4) and 36 (CID7). Thus, the number of participants needed for the intervention
was 1802. To allow an estimated drop-out of 25% as a result of failure to lose >8% of initial body weight
during the two-month LCD period, the number of participants required to be enrolled into PREVIEW
was initially estimated to be 2403.
The primary data are analysed statistically using the principle of ‘intention-to-treat’ (ITT cohort)
and also as a completers’ cohort. A ‘completer’ is defined as a participant who has remained in the
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trial for the full three year intervention period, or who has been diagnosed with T2D before the end of
the intervention.
The primary outcome in the adults’ trial is incidence of T2D. For statistical analysis assessing the
effect of the two diets on the T2D is a ‘semi-parametric Cox proportional hazards regression model’.
Missing data are addressed using hot-deck imputation. Missing covariate information is addressed
using multiple imputation. Sensitivity analyses (e.g., complete-case analyses without drop-outs) will
be carried out to assess if censoring was informative or non-informative.
For statistical analysis of the continuous secondary outcomes (e.g., blood chemistry, anthropometrics,
etc.) a ‘linear mixed model’ is used. For the categorical outcomes (e.g., sex, educational attainment,
proportion of subjects maintaining a defined weight loss, etc.), the type of statistical analysis is ‘logistic’
or ‘ordinal mixed-effects model’. The parameter of interest is the difference in odds ratio between the
intervention groups. Although the main statistical analyses will be done by using the entire cohort,
one of the most important stratified analyses will use an age-group (e.g., above and below 65 years)
stratification. By comparing older against younger participants we might obtain new insight on
whether dietary protein content in this respect has different effects on, e.g., body composition, weight,
and clinical variables.
2.10. Ethical Issues
The study protocol and amendments were reviewed and approved by local Human Ethics
Committees at all study sites. The work of PREVIEW is carried out in full compliance with the relevant
requirements of the latest version of the Declaration of Helsinki (59th WMA General Assembly, Seoul,
Korea, October 2008), and the ICH-GCP, The International Conference on Harmonisation (ICH) for
Good Clinical Practice to the extent that this is possible and relevant. All participants provided written
informed consent prior to commencing screening procedures in clinic. All information obtained during
the trial is handled according to local regulations and the European Directive 95/46/CE (directive on
protection of individuals with regard to the processing of personal data and on the free movement of
such data). The trial is registered with ClinicalTrials.gov, NCT01777893.
3. Results
As PREVIEW is an on-going trial, only results obtained from participant screening and baseline
phases are presented here. Screening was conducted from June 2013 to February 2015. On average,
35% of the pre-screened individuals were eligible for the laboratory screening. Further, 43% of the
screened participants were found to be eligible for the trial. In total, 2326 overweight, pre-diabetic
adults were enrolled and randomised into the trial. This was 97% of the original pre-specified target
(Figure 2). Approximately half of the participants were 55–70 years at baseline (Table 4).
Baseline characteristics from blood biochemistry and anthropometric assessments are shown
assigned to each intervention group in Table 5. The basic characteristics of the groups are similar.
A notable feature of the participants is that the mean baseline fasting glucose concentration was
approximately at the mid of the eligibility range, whereas the mean 2-h glucose concentration was
at the lower cut-off point. According to the OGTT laboratory data, 1389 (62%) of all participants had
increased fasting glucose at baseline, 506 (23%) had impaired glucose tolerance and 286 (13%) had both
of these pre-diabetic indicators. At baseline (CID1), 25 participants (1%)—who all had been diagnosed
with pre-diabetes at screening—were not diagnosed with pre-diabetes anymore. The prevalence of
pre-diabetes described above were not significantly different between the four study groups.
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Table 4. Number and age distribution of participants recruited for the PREVIEW intervention trial.
Site Pre-Screened Screened Randomised (n) Men (n) Women (n) Age 25–45 Years (n) Age 46–54 Years (n) Age 55–70 Years (n) Mean Age Years (SD)
UCPH 2061 908 379 159 220 86 62 233 54.2 (10.9)
HEL 1269 633 289 88 201 39 33 221 58.2 (8.9)
UM 675 553 203 94 109 42 17 145 56.6 (10.0)
UNOTT 3914 979 264 102 162 95 42 133 51.6 (12.0)
UNAV 1740 732 307 93 214 145 82 93 47.5 (10.6)
MU 1190 488 368 87 281 190 7 158 47.8 (12.0)
UNSYD 3108 595 195 56 139 59 36 102 53.0 (10.8)
UOA 1654 584 321 77 244 156 47 103 47.0 (11.4)
Total 15,611 5472 2326 756 1570 812 326 1188 51.6 (11.6)
Abbreviations for study sites: UCPH = University of Copenhagen (Denmark); HEL = University of Helsinki (Finland); UM = Maastricht University (The Netherlands); UNOTT = University
of Nottingham (UK); UNAV = University of Navarra (Spain); MU = Medical University of Sofia (Bulgaria); UNSYD = University of Sydney (Australia); UOA = University of Auckland
(New Zealand).
Table 5. Number of participants, age, anthropometric results, blood chemistry, and blood pressure for all intervention groups, assessed at baseline (CID1) before
weight reduction. The results are shown as the mean (±SD).
HP: Higher Protein (25 E%)
Moderate Carbohydrate (45 E%)
Low GI (≤50) Diet
MP: Moderate Protein (15 E%)
Higher Carbohydrate (55 E%)
Medium GI (≥56) Diet
Moderate-Intensity Physical Activity High-Intensity Physical Activity Moderate-Intensity Physical Activity High-Intensity Physical Activity
No. (men/women) 556 (184/372) 556 (177/379) 559 (180/379) 553 (179/374)
Age, years 51.6 ± 11.5 51.8 ± 11.7 51.4 ± 11.2 51.4 ± 11.8
Anthropometrics
Height, cm 168 ± 9 168 ± 9 168 ± 9 168 ± 10
Weight, kg 99.3 ± 20.8 100.6 ± 21.0 101.6 ± 22.6 98.7 ± 20.9
Body Mass Index, kg/m2 35.1 ± 6.5 35.6 ± 6.7 35.7 ± 6.6 35.0 ± 6.4
Waist circumference, cm 109.6 ± 15.2 111.0 ± 15.3 111.1 ± 15.4 109.6 ± 14.5
Hip circumference, cm 117.6 ± 14.5 118.8 ± 14.8 119.2 ± 13.9 117.8 ± 13.8
Body fat (% of weight) 43.0 ± 7.5 43.5 ± 7.5 43.5 ± 7.9 43.1 ± 7.8
Blood chemistry and blood pressure
f P-glucose, mmol/L 6.2 ± 0.8 6.2 ± 0.6 6.2 ± 0.7 6.2 ± 0.8
2hP-glucose, mmol/L 7.8 ± 2.3 7.7 ± 2.25 7.5 ± 2.2 7.7 ± 2.1
fP-insulin, mU/L 13.6 ± 7.9 14.0 ± 8.7 13.2 ± 7.7 13.1 ± 7.2
HbA1c, mmol/mol 36.6 ± 3.9 36.8 ± 3.9 36.7 ± 4.2 36.7 ± 4.0
Cholesterol, mmol/L 5.2 ± 1.0 5.1 ± 1.0 5.3 ± 1.0 5.1 ± 1.0
LDL cholesterol, mmol/L 3.3 ± 0.9 3.2 ± 0.8 3.3 ± 0.9 3.2 ± 0.8
HDL cholesterol, mmol/L 1.3 ± 0.3 1.3 ± 0.3 1.3 ± 0.3 1.3 ± 0.3
Triglycerides, mmol/L 1.5 ± 0.8 1.5 ± 0.7 1.5 ± 0.9 1.5 ± 0.8
CRP, mg/L 5.3 ± 6.3 6.0 ± 8.7 5.2 ± 5.1 5.1 ± 7.5
Systolic BP, mmHg 128.5 ± 15.6 129.7 ± 16.2 128.7 ± 16.3 129.3 ± 15.5
Diastolic BP, mmHg 78.2 ± 10.9 77.6 ± 11.2 78.4 ± 11.5 78.3 ± 10.7
GI = glycaemic index; BP = blood pressure.
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PREVIEW is a much larger trial than both the Finnish DPS (n = 522) [11] and Chinese Da Qing
study (n = 577) [9], although smaller than the DPP (n = 3234) [10]. However, in the DPP a third of
the participants received ‘Metformin’ in addition to dietary advice; hence, the number of participants
without medical treatment, but adhering to lifestyle intervention (diet and physical activity) was
2161, which is similar to PREVIEW. Of the above interventions, the geographical and ethnic variation
is greatest in PREVIEW. The age-range of participants in DPP and DPS was 33–67 years, slightly
narrower than in PREVIEW, but the mean age of participants is similar across the studies (50–55 years).
The large proportion of older participants in PREVIEW, (>55 years), was expected since the risk for
T2D increases with age [2], and due to the growing health consciousness of this age group, many of
whom are retired and have the time to participate in a demanding intervention. The smaller proportion
of middle age-adults is also explained by later initiation of recruitment in this age group, compared
with younger and older participants. In general, finding an adequate number of pre-diabetic subjects
was a real challenge in most countries, given the “hidden” status of this condition. Thus, recruitment
took about three times as long as planned from the beginning of the project.
One major challenge in PREVIEW is related to adherence to the diet and physical activity
programs. The HP-diet is novel and, with the higher protein content, also somewhat outside the current
boundaries of nutritional guidelines [42,43]. Whether the HP diet results in better adherence than the
MP diet with high CHO and whole-grain cereal intakes is one of the key interests in PREVIEW. Nutrient
intakes and food consumption patterns will be assessed in PREVIEW by repeated 4-d diet-records.
The poor accuracy of dietary assessment is well known [44], but it is expected that the difference
in dietary protein and CHO intakes should be sufficiently large to be detected using this method.
Moreover, protein intake is verified using 24 h urinary nitrogen excretion [45].
It may be more difficult to create a verifiable difference for GI than for protein-to-CHO ratio.
Whilst GI values of foods have been shown to provide a good summary of postprandial glycaemia [46],
difficulties in attributing GI values to foods for which there are no validated data available may add
to the variability [47], particularly in a multi-centre intervention such as PREVIEW. In DiOGenes,
the reported observed difference in mean dietary GI was small (56 vs. 60 units) [19] which increases
the requirements of precision.
The physical activity intervention in PREVIEW is not a supervised training programme.
Participants are expected to integrate activity into their daily lives and use local opportunities to
achieve their goals. To improve adherence, there is flexibility with the type of activities chosen.
A combination of measures of physical activity is used to analyse the compliance to the type of
intervention and our methods allow a description of activities that were used to achieve this.
It is probable that the HI-program will be more challenging in the long-term. Warming-up,
cooling-down, muscular conditioning exercises, and stretching are carefully explained to the
participants in order to decrease the risk for injuries. It should be noted that the HI-program in
PREVIEW is not high-intensity interval-training (HIIT). While there are some data on potential
benefits from HIIT on cardiovascular function and glucose metabolism [48], we considered the data on
feasibility and long-term maintenance of this kind of training still too limited.
In addition to good compliance of the programmes, keeping the drop-out rate as low as possible
will be challenging. Frequent contact with the research staff is one way to reduce the drop-out rate.
However, PREVIEW has been planned to study how behavioural change is realized under ‘real-life’
conditions and, hence, the fading visit design where group visits are infrequent during years two and
three of the intervention. Adherence is encouraged through a number of practices, including use of
specific behavioural change techniques [31], such as implementation intentions, or Facebook groups,
one for each randomised group, to promote attendance at group visits and CIDs. In addition, the sites
can also conduct general information lectures, physical activity sessions, and/or send a newsletter to
the participants, once or twice a year.
Compared to DPS and DPP studies, a particular feature of PREVIEW is related to the different
settings in which the intervention is conducted, including not only genetic background, but also attitudes,
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norms, and socio-economic features. Although the participating countries are well-developed,
considerable variations exist, e.g., regarding food attitudes and habits, as well as traditions of practicing
physical activity.
The unique feature in the PREVIEW intervention is the direct comparison of two potentially
efficacious diet and physical activity intervention programs. Hence, PREVIEW has a clear potential to
identify a recommended optimal diet and physical activity programme to prevent T2D, a programme
which is also suitable across different countries. It is also possible, however, that PREVIEW data will
demonstrate that there are several, equally efficacious alternatives. Clearly, both answers are important
from a public health viewpoint.
Supplementary Materials: The following are available online at www.mdpi.com/2072-6643/9/6/632/s1,
Table S1: Inclusion and exclusion criteria in the PREVIEW screening, Table S2: Questionnaires on moderators,
mediators, behaviour, and social environment.
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